Literature DB >> 25700650

Pharmacological characterization of mGlu1 receptors in cerebellar granule cells reveals biased agonism.

Hannah A Hathaway1, Sergey Pshenichkin2, Ewa Grajkowska2, Tara Gelb2, Andrew C Emery3, Barry B Wolfe2, Jarda T Wroblewski2.   

Abstract

The majority of existing research on the function of metabotropic glutamate (mGlu) receptor 1 focuses on G protein-mediated outcomes. However, similar to other G protein-coupled receptors (GPCR), it is becoming apparent that mGlu1 receptor signaling is multi-dimensional and does not always involve G protein activation. Previously, in transfected CHO cells, we showed that mGlu1 receptors activate a G protein-independent, β-arrestin-dependent signal transduction mechanism and that some mGlu1 receptor ligands were incapable of stimulating this response. Here we set out to investigate the physiological relevance of these findings in a native system using primary cultures of cerebellar granule cells. We tested the ability of a panel of compounds to stimulate two mGlu1 receptor-mediated outcomes: (1) protection from decreased cell viability after withdrawal of trophic support and (2) G protein-mediated phosphoinositide (PI) hydrolysis. We report that the commonly used mGlu1 receptor ligands quisqualate, DHPG, and ACPD are completely biased towards PI hydrolysis and do not induce mGlu1 receptor-stimulated neuroprotection. On the other hand, endogenous compounds including glutamate, aspartate, cysteic acid, cysteine sulfinic acid, and homocysteic acid stimulate both responses. These results show that some commonly used mGlu1 receptor ligands are biased agonists, stimulating only a fraction of mGlu1 receptor-mediated responses in neurons. This emphasizes the importance of utilizing multiple agonists and assays when studying GPCR function.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biased agonism; Cerebellar granule cells; DHPG; Glutamate; Metabotropic glutamate receptor 1; Quisqualate

Mesh:

Substances:

Year:  2015        PMID: 25700650      PMCID: PMC4387075          DOI: 10.1016/j.neuropharm.2015.02.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  44 in total

Review 1.  Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?

Authors:  Filippo Caraci; Giuseppe Battaglia; Maria Angela Sortino; Simona Spampinato; Gemma Molinaro; Agata Copani; Ferdinando Nicoletti; Valeria Bruno
Journal:  Neurochem Int       Date:  2012-01-25       Impact factor: 3.921

2.  JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist.

Authors:  Hilde Lavreysen; Ria Wouters; François Bischoff; Sandrina Nóbrega Pereira; Xavier Langlois; Saskia Blokland; Marijke Somers; Lieve Dillen; Anne S J Lesage
Journal:  Neuropharmacology       Date:  2004-12       Impact factor: 5.250

Review 3.  Beta-arrestins and cell signaling.

Authors:  Scott M DeWire; Seungkirl Ahn; Robert J Lefkowitz; Sudha K Shenoy
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

4.  What is pharmacological 'affinity'? Relevance to biased agonism and antagonism.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2014-07-17       Impact factor: 14.819

5.  Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.

Authors:  Jin Namkoong; Seung-Shick Shin; Hwa Jin Lee; Yarí E Marín; Brian A Wall; James S Goydos; Suzie Chen
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

6.  Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2.

Authors:  Jesper Mosolff Mathiesen; Trond Ulven; Lene Martini; Lars Ole Gerlach; Akos Heinemann; Evi Kostenis
Journal:  Mol Pharmacol       Date:  2005-05-03       Impact factor: 4.436

7.  Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1.

Authors:  Velina Guergueltcheva; Dimitar N Azmanov; Dora Angelicheva; Katherine R Smith; Teodora Chamova; Laura Florez; Michael Bynevelt; Thai Nguyen; Sylvia Cherninkova; Veneta Bojinova; Ara Kaprelyan; Lyudmila Angelova; Bharti Morar; David Chandler; Radka Kaneva; Melanie Bahlo; Ivailo Tournev; Luba Kalaydjieva
Journal:  Am J Hum Genet       Date:  2012-08-16       Impact factor: 11.025

8.  Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation - possible role as a dependence receptor.

Authors:  Sergey Pshenichkin; Monika Dolińska; Małgorzata Klauzińska; Victoria Luchenko; Ewa Grajkowska; Jarda T Wroblewski
Journal:  Neuropharmacology       Date:  2008-06-27       Impact factor: 5.250

9.  Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling.

Authors:  Andrew C Emery; John O DiRaddo; Eric Miller; Hannah A Hathaway; Sergey Pshenichkin; Guy Rodrigue Takoudjou; Ewa Grajkowska; Robert P Yasuda; Barry B Wolfe; Jarda T Wroblewski
Journal:  Mol Pharmacol       Date:  2012-05-14       Impact factor: 4.436

10.  Functional effects of GRM1 suppression in human melanoma cells.

Authors:  Janet Wangari-Talbot; Brian A Wall; James S Goydos; Suzie Chen
Journal:  Mol Cancer Res       Date:  2012-07-13       Impact factor: 5.852

View more
  7 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

2.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Authors:  Kathy Sengmany; Junaid Singh; Gregory D Stewart; P Jeffrey Conn; Arthur Christopoulos; Karen J Gregory
Journal:  Neuropharmacology       Date:  2016-07-05       Impact factor: 5.250

3.  Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.

Authors:  Kathy Sengmany; Shane D Hellyer; Sabine Albold; Taide Wang; P Jeffrey Conn; Lauren T May; Arthur Christopoulos; Katie Leach; Karen J Gregory
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

Review 4.  Control of neuronal excitability by Group I metabotropic glutamate receptors.

Authors:  Ana Maria Bernal Correa; Jennifer Diniz Soares Guimarães; Everton Dos Santos E Alhadas; Christopher Kushmerick
Journal:  Biophys Rev       Date:  2017-08-23

5.  β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X.

Authors:  Laura J Stoppel; Benjamin D Auerbach; Rebecca K Senter; Anthony R Preza; Robert J Lefkowitz; Mark F Bear
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

6.  Transduction of group I mGluR-mediated synaptic plasticity by β-arrestin2 signalling.

Authors:  Andrew G Eng; Daniel A Kelver; Tristan P Hedrick; Geoffrey T Swanson
Journal:  Nat Commun       Date:  2016-11-25       Impact factor: 14.919

Review 7.  Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?

Authors:  Simona Federica Spampinato; Agata Copani; Ferdinando Nicoletti; Maria Angela Sortino; Filippo Caraci
Journal:  Front Mol Neurosci       Date:  2018-11-13       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.